C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of “Moderate Buy” from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $7.75.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Friday, July 17th.

C4 Therapeutics Trading Down 4.9%

Shares of CCCC stock opened at $3.48 on Friday. The stock has a 50 day simple moving average of $3.94 and a 200-day simple moving average of $3.08. The company has a market cap of $384.78 million, a price-to-earnings ratio of -2.92 and a beta of 2.90. C4 Therapeutics has a 12-month low of $1.69 and a 12-month high of $5.17.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.05. The firm had revenue of $6.15 million for the quarter, compared to the consensus estimate of $4.42 million. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. On average, equities analysts forecast that C4 Therapeutics will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CCCC. SummitTX Capital L.P. purchased a new stake in C4 Therapeutics during the first quarter valued at about $28,000. CTC Alternative Strategies Ltd. purchased a new position in shares of C4 Therapeutics in the 1st quarter worth about $28,000. Zacks Investment Management acquired a new position in shares of C4 Therapeutics in the 3rd quarter valued at about $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of C4 Therapeutics in the 3rd quarter valued at about $43,000. Finally, Delta Investment Management LLC purchased a new stake in shares of C4 Therapeutics during the 4th quarter worth about $38,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.